Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Van Hemelrijck, Mieke"'
Autor:
Moore CM; Division of Surgical and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals Trust, London, UK. Electronic address: caroline.moore@ucl.ac.uk., King LE; Movember, Richmond, Victoria, Australia., Withington J; Division of Surgical and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals Trust, London, UK., Amin MB; Department of Pathology and Lab Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA., Andrews M; Patient Advocate, England, UK., Briers E; Patient Advocate, Hasselt, Belgium., Chen RC; Department of Radiation Oncology, University of Kansas Cancer Center, Kansas City, KS, USA., Chinegwundoh FI; Department of Urology, Barts Health NHS Trust, London, UK; City University of London, London, UK., Cooperberg MR; Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Urology, University of California at San Francisco, San Francisco, CA, USA., Crowe J; Australian Prostate Centre, North Melbourne, Victoria, Australia., Finelli A; Department of Surgery (Urology), Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada; Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, Toronto, ON, Canada., Fitch MI; Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada., Frydenberg M; Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia; Department of Urology, Cabrini Institute, Cabrini Health, Melbourne, Victoria, Australia., Giganti F; Division of Surgical and Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK., Haider MA; Joint Department of Medical Imaging, University Health Network, Sinai Health System and University of Toronto, Toronto, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada., Freeman J; Patient Advocate, England, UK., Gallo J; Active Surveillance Patients International, East Stroudsburg, PA, USA., Gibbs S; Patient Advocate, England, UK., Henry A; The Walnut Foundation, Brampton, ON, Canada., James N; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Kinsella N; Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK; Department of Urology, Royal Marsden Hospital, London, UK., Lam TBL; Academic Urology Unit, Aberdeen University, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK., Lichty M; Active Surveillance Patients International, East Stroudsburg, PA, USA., Loeb S; Department of Urology, New York University, New York, NY, USA; Department of Population Health, New York University, New York, NY, USA; Manhattan Veterans Affairs Medical Center, New York, NY, USA., Mahal BA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Mastris K; Tackle Prostate Cancer, London UK., Mitra AV; Cancer Services, University College London Hospitals, NHS, London, UK., Merriel SWD; Exeter Collaboration for Academic Primary Care (APEx), University of Exeter, Exeter, UK; Centre for Primary Care & Health Services Research, University of Manchester, Manchester, UK., van der Kwast T; Department of Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada., Van Hemelrijck M; Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK., Palmer NR; Department of Medicine, Zuckerberg San Francisco General Hospital. University of California San Francisco School of Medicine; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco; Department of Urology, University of California San Francisco School of Medicine, San Francisco, CA, USA., Paterson CC; School of Nursing, Midwifery and Public Health, University of Canberra, Bruce, Australian Capital Territory, Australia; Canberra Health Services and ACT Health, Synergy Nursing and Midwifery Research Centre, Canberra Hospital, Garran, Australian Capital Territory, Australia., Roobol MJ; Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Segal P; Prostate Cancer Support Toronto, Toronto, ON, Canada., Schraidt JA; ZERO - The End of Prostate Cancer, Alexandria, VA, USA., Short CE; Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia; Melbourne Centre for Behaviour Change, University of Melbourne, Melbourne, Victoria, Australia., Siddiqui MM; Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA., Tempany CMC; Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Villers A; Department of Urology Univ. Lille, CHU Lille, Department of Urology F-59000 Lille, France., Wolinsky H; Answer Cancer Foundation, Tumacacori, Arizona, USA; TheActiveSurveillor.com, Flossmoor, Illinois, USA., MacLennan S; Academic Urology Unit, Aberdeen University, Aberdeen, UK.
Publikováno v:
European urology oncology [Eur Urol Oncol] 2023 Apr; Vol. 6 (2), pp. 160-182. Date of Electronic Publication: 2023 Jan 27.
Autor:
Marsden T; Division of Surgical and Interventional Sciences, University College London, London, UK teresa.marsden@ucl.ac.uk.; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK., Lomas DJ; Department of Urology, Mayo Clinic, Rochester, New York, USA., McCartan N; Division of Surgical and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK., Hadley J; Division of Surgical and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK., Tuck S; ReIMAGINE Consortium Patient Representative, University College London, London, UK., Brown L; MRC Clinical Trials Unit, University College London, London, UK., Haire A; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Moss CL; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Green S; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Van Hemelrijck M; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Coolen T; London Institute for Mathematical Sciences, London, UK., Santaolalla A; Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK., Isaac E; Centre for Medical Imaging, University College London, London, UK., Brembilla G; Centre for Medical Imaging, University College London, London, UK., Kopcke D; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK., Giganti F; Division of Surgical and Interventional Sciences, University College London, London, UK.; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK., Sidhu H; Centre for Medical Imaging, University College London, London, UK., Punwani S; Centre for Medical Imaging, University College London, London, UK., Emberton M; Division of Surgical and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK., Moore CM; Division of Surgical and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Publikováno v:
BMJ open [BMJ Open] 2021 Sep 30; Vol. 11 (9), pp. e048144. Date of Electronic Publication: 2021 Sep 30.
Autor:
Beckmann K; Translational Oncology and Urology Research, Comprehensive Cancer Centre, King's College London, London, United Kingdom.; University of South Australia Cancer Research Institute, University of South Australia, Adelaide, Australia.; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Crawley D; Translational Oncology and Urology Research, Comprehensive Cancer Centre, King's College London, London, United Kingdom., Nordström T; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Aly M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Olsson H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Lantz A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Binti Abd Jalal N; Translational Oncology and Urology Research, Comprehensive Cancer Centre, King's College London, London, United Kingdom., Garmo H; Regional Cancer Centre, Uppsala, Sweden., Adolfsson J; Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden., Eklund M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Van Hemelrijck M; Translational Oncology and Urology Research, Comprehensive Cancer Centre, King's College London, London, United Kingdom.; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
JAMA network open [JAMA Netw Open] 2019 Nov 01; Vol. 2 (11), pp. e1914689. Date of Electronic Publication: 2019 Nov 01.
Autor:
Beckmann K; Translational Oncology & Urology Research, Comprehensive Cancer Centre, King's College London, 3rd Floor, Bermondsey Wing, Guy's Hospital, London, SE1 9RT, UK. Kerri.beckmann@kcl.ac.uk.; University of South Australia, Centre for population Health Research Adelaide Australia, Adelaide, Australia. Kerri.beckmann@kcl.ac.uk., Kinsella N; Translational Oncology & Urology Research, Comprehensive Cancer Centre, King's College London, 3rd Floor, Bermondsey Wing, Guy's Hospital, London, SE1 9RT, UK.; Department of Urology, The Royal Marsden Hospital, London, UK., Olsson H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Wallerstedt Lantz A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Nordstrom T; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Aly M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Adolfsson J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; CLINTEC-Department, Karolinska Institutet, Stockholm, Sweden., Eklund M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Van Hemelrijck M; Translational Oncology & Urology Research, Comprehensive Cancer Centre, King's College London, 3rd Floor, Bermondsey Wing, Guy's Hospital, London, SE1 9RT, UK.; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
BMC urology [BMC Urol] 2019 Aug 05; Vol. 19 (1), pp. 73. Date of Electronic Publication: 2019 Aug 05.
Autor:
Van Hemelrijck M; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. Electronic address: Mieke.vanhemelrijck@kcl.ac.uk., Ji X; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA., Helleman J; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands., Roobol MJ; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Linden W; Department of Professional Health Solutions & Services, Philips Research, Eindhoven, The Netherlands., Nieboer D; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands., Bangma CH; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands., Frydenberg M; Department of Surgery, Monash University, Melbourne, Australia; Department of Urology, Monash Health, Melbourne, Australia., Rannikko A; Helsinki University and Helsinki University Hospital, Helsinki, Finland., Lee LS; Department of Urology, Singapore General Hospital, Singapore., Gnanapragasam VJ; Academic Urology Group, Department of Surgery and Oncology, University of Cambridge, Cambridge, UK., Kattan MW; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Publikováno v:
European urology [Eur Urol] 2019 Mar; Vol. 75 (3), pp. 523-531. Date of Electronic Publication: 2018 Oct 29.
Autor:
MacAskill F; Department of Urology, Southend University Hospital, Westcliff-on-Sea, Essex, UK., Lee SM; Department of Urology, Southend University Hospital, Westcliff-on-Sea, Essex, UK. smlee84@gmail.com.; Department of Urology, Weston General Hospital, Weston-super-Mare, Somerset, UK. smlee84@gmail.com., Eldred-Evans D; Department of Urology, Guy's Hospital, London, UK., Wulaningsih W; Division of Cancer Studies, Cancer Epidemiology Group, King's College London, London, UK., Popert R; Department of Urology, Guy's Hospital, London, UK.; London Bridge Hospital, London, UK., Wolfe K; Department of Pathology, Southend University Hospital, Westcliff-on-Sea, Essex, UK., Van Hemelrijck M; Division of Cancer Studies, Cancer Epidemiology Group, King's College London, London, UK., Rottenberg G; London Bridge Hospital, London, UK.; Department of Radiology, Guy's Hospital, London, UK., Liyanage SH; Department of Radiology, Southend University Hospital, Westcliff-on-Sea, Essex, UK., Acher P; Department of Urology, Southend University Hospital, Westcliff-on-Sea, Essex, UK.; London Bridge Hospital, London, UK.
Publikováno v:
International urology and nephrology [Int Urol Nephrol] 2017 Aug; Vol. 49 (8), pp. 1335-1342. Date of Electronic Publication: 2017 May 05.
Autor:
Nderitu P; Department of Oncology, Guy's Hospital, London, UK., Van Hemelrijck M; Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK., Ashworth M; Department of Primary Care and Public Health Sciences, King's College London, London, UK., Mathur R; Centre for Primary Care and Public Health, Queen Mary University of London, London, UK., Hull S; Centre for Primary Care and Public Health, Queen Mary University of London, London, UK., Dudek A; Department of Oncology, Guy's Hospital, London, UK., Chowdhury S; Department of Oncology, Guy's Hospital, London, UK.
Publikováno v:
BMJ open [BMJ Open] 2016 Jul 12; Vol. 6 (7), pp. e011356. Date of Electronic Publication: 2016 Jul 12.
Autor:
Holmberg L; Department of Surgical Sciences, Uppsala University Regional Cancer Center University Hospital, Uppsala, Sweden, lars.holmberg@kcl.ac.uk., Van Hemelrijck M
Publikováno v:
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer [Recent Results Cancer Res] 2014; Vol. 202, pp. 1-7.
Autor:
Beckmann, Kerri, Santaolalla, Aida, Sugimoto, Mikio, Carroll, Peter, Rubio, Jose, Villers, Arnauld, Bjartell, Anders, Morgan, Todd, Dasgupta, Prokar, Van Hemelrijck, Mieke, Elhage, Oussama, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
Publikováno v:
Prostate cancer and prostatic diseases, vol 26, iss 2
BackgroundCurrently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::9c99680c86f1ed8249c4298ddae8a8e3
https://escholarship.org/uc/item/5dk12186
https://escholarship.org/uc/item/5dk12186
Autor:
Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
Publikováno v:
European urology, vol 75, iss 3
BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::fc9bff0da321deba5b8d0ce9c3323f00
https://escholarship.org/uc/item/69n476qf
https://escholarship.org/uc/item/69n476qf